期刊
MOLECULAR CELL
卷 33, 期 1, 页码 117-123出版社
CELL PRESS
DOI: 10.1016/j.molcel.2008.11.021
关键词
-
资金
- CRUK [CRUK C20600/A6620]
- MRC
- Medical Research Council [G0001129] Funding Source: researchfish
- MRC [G0001129] Funding Source: UKRI
For a cancer cell to resist treatment with drugs that trap topoisomerases covalently on the DNA, the topoisomerase must be removed. In this study, we provide evidence that the Schizosaccharomyces pombe Rad32(Mre11) nuclease activity is involved in the removal of both Top2 from 5' DNA ends as well as Top1 from 3' ends in vivo. A ctp1(ctIP) deletion is defective for Top2 removal but overproficient for Top1 removal, suggesting that Ctp1(ctIP) plays distinct roles in removing topoisomerases from 5' and 3' DNA ends. Analysis of separation of function mutants suggests that MRN-dependent topoisomerase removal contributes significantly to resistance against topoisomerase-trapping drugs. This study has important implications for our understanding of the role of the MRN complex and CtIP in resistance of cells to a clinically important group of anticancer drugs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据